

Special Issue

Advances in Pharmaceutics, Genomics, and Biotechnology for Liver Disease Therapy

Message from the Guest Editor

Liver disease incidence is rising globally, including MASLD, hepatitis, cirrhosis, and hepatocellular carcinoma, highlighting the urgent need for innovative treatments. Advances in pharmacology, genomics, and biotechnology are transforming diagnosis and therapy. New pharmacological approaches involve nanocarriers, immunomodulators, and antifibrotics to improve liver targeting and efficacy. Genomic tools like next-generation sequencing and GWAS enable personalized therapies, such as lipid nanoparticles tailored to genetic variants (e.g., CYP450, PNPLA3). Biotechnological innovations—like bioengineered liver scaffolds and exosome-based regenerative delivery—offer promising regenerative strategies. Integrating these disciplines enhances understanding and patient outcomes for complex liver conditions. This Special Issue aims to explore emerging approaches, expanding knowledge and guiding the development of novel therapeutics.

Guest Editor

Prof. Dr. Juan Socorro Armendariz-Borunda
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud,
Campus Guadalajara, Zapopan P.C. 45138, Mexico

Deadline for manuscript submissions

31 August 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/248874

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).